Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R James White

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The Lancet. Respiratory Medicine|October 18, 2016
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION studyMarius M Hoeper, Vallerie V McLaughlin, Joan Albert Barberá, et al.
Advances in Therapy|December 6, 2023
Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label ExtensionEkkehard Grünig, Franck Rahaghi, Jean Elwing, et al.
American Journal of Respiratory and Critical Care Medicine|March 2, 2021
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled TrialRoham T Zamanian, David Badesch, Lorinda Chung, et al.
The Lancet. Respiratory Medicine|February 23, 2025
Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patientsFranck F Rahaghi, Marc Humbert, Marius M Hoeper, et al.
Vascular Pharmacology|September 12, 2024
Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensusGiovanna Manzi, Raymond L Benza, Paola Argiento, et al.
The New England Journal of Medicine|August 27, 2015
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial HypertensionNazzareno Galiè, Joan A Barberà, Adaani E Frost, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
The Lancet. Respiratory Medicine|March 27, 2021
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialMarius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, et al.
American Journal of Respiratory and Critical Care Medicine|December 14, 2021
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?Carmine Dario Vizza, Irene M Lang, Roberto Badagliacca, et al.
The Lancet. Respiratory Medicine|December 12, 2018
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysisChristopher J Rhodes, Ken Batai, Marta Bleda, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The Lancet. Respiratory Medicine|October 18, 2016
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION studyMarius M Hoeper, Vallerie V McLaughlin, Joan Albert Barberá, et al.
Advances in Therapy|December 6, 2023
Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label ExtensionEkkehard Grünig, Franck Rahaghi, Jean Elwing, et al.
American Journal of Respiratory and Critical Care Medicine|March 2, 2021
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled TrialRoham T Zamanian, David Badesch, Lorinda Chung, et al.
The Lancet. Respiratory Medicine|February 23, 2025
Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patientsFranck F Rahaghi, Marc Humbert, Marius M Hoeper, et al.
Vascular Pharmacology|September 12, 2024
Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensusGiovanna Manzi, Raymond L Benza, Paola Argiento, et al.
The New England Journal of Medicine|August 27, 2015
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial HypertensionNazzareno Galiè, Joan A Barberà, Adaani E Frost, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
The Lancet. Respiratory Medicine|March 27, 2021
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialMarius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, et al.
American Journal of Respiratory and Critical Care Medicine|December 14, 2021
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?Carmine Dario Vizza, Irene M Lang, Roberto Badagliacca, et al.
The Lancet. Respiratory Medicine|December 12, 2018
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysisChristopher J Rhodes, Ken Batai, Marta Bleda, et al.
Pageof 7